Boundless Bio Appoints Amy Berkley, Ph.D., as Vice President, Program Team Leadership and Strategic Alliances

- Dr. Berkley has 20 years of experience managing drug development programs, from discovery to clinical proof of concept and late-stage clinical development -

Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that Amy Berkley has been appointed as Vice President of Program Team Leadership and Strategic Alliances.

“We are excited to have Amy join the team,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. “Amy brings significant experience in program team leadership and alliance management and will play a critical role in driving our lead ecDNA-directed therapeutic programs, or ecDTx, through first in human studies as well as advancing earlier stage programs that we innovate.”

Prior to joining Boundless Bio, Amy served as Head of Alliance Management at Ionis Pharmaceuticals, where she managed over 30 programs with pharmaceutical and biotech partners from discovery through clinical development. Prior to Ionis, Amy spent nine years at Halozyme in Alliance Management and served as the Program Manager for the Company’s lead oncology asset, advancing it from pre-clinical to phase 3 clinical trials. While at Halozyme, she successfully managed the approval of several partnered oncology products and the progression of multiple partnered products through first in human studies. Amy holds a Ph.D. in molecular and cellular biology from the University of California, San Diego and completed a postdoctoral fellowship in cardiology at the David Geffen School of Medicine at the University of California, Los Angeles.

“Boundless Bio is one of the most exciting and innovative companies in precision oncology today,” said Dr. Berkley. “The study of ecDNA is enabling a new understanding of gene amplification driven cancers and driving new therapeutic options for this high unmet need segment of the cancer population. There are many patients that may benefit from Boundless Bio’s current pipeline of ecDTx therapies. I’m delighted to join this team.”

About Boundless Bio

Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

For more information, visit www.boundlessbio.com.

Follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220207005019/en/